BNTC Gene Therapy Penny Stock at All Time Low

NASDAQ:BNTC   Benitec Biopharma Inc.
BNTC Benitec Biopharma Inc is a development-stage biotechnology company which focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference based therapeutics.

BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc. and Morgan Stanley have stakes in it.

On 2/17/2022 P. Trucchio from HC Wainwright brokerage Initiated Coverage for BNTC with a Buy rating and a price target of $10.00.

The price of the stock can easily double in my opinion.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.